PURPOSE/ OBJECTIVES: Adjuvant endocrine therapy (AET) has been shown to improve survival in hormone receptor-positive breast cancer survivors, but as many as half do not complete recommended treatment. Management of medication-related side effects and engagement with providers are two potentially modifiable factors, but their associations with adherence are not well understood. The aims were to build on survey results to qualitatively explore survivors' experiences with prescribed AET to (a) describe appraisal and management of AET side effects and (b) deconstruct decisions to initiate, discontinue, or maintain AET. . RESEARCH APPROACH: The authors used a mixed-methods explanatory sequence research design with a qualitative emphasis. . SETTING: Survivors were recruited from a clinical cancer registry maintained at the University of Texas Southwestern Medical Center, which includes the Harold C. Simmons Comprehensive Cancer Center (National Cancer Institute-designated), in Dallas. . PARTICIPANTS: 452 survivors completed a survey, and 30 took part in telephone interviews. . METHODOLOGIC APPROACH: Qualitative methods were used in which the authors recorded and transcribed interviews for analysis and used open coding to reduce data into themes. . FINDINGS: Among adherent survivors, the themes of tolerance of side effects and perseverance were strong. Nonadherent survivors expressed more difficulty managing side effects and perceived fewer benefits when side effects were bothersome. The most common side effects mentioned by all survivors were menopausal symptoms and joint pain; less common side effects were cognitive decline and cardiac distress. Some sought advice from their oncology team. Nonadherent survivors appeared initially motivated to maintain AET but identified a tolerance limit for side effects after which a provider's recommendation was less influential in their decision to maintain or discontinue AET. . INTERPRETATION: This study elucidated adherence as a complex continuum of behaviors, appraisals, and decision points. These insights may be particularly useful in counseling survivors taking AET and promoting timely delivery of clinical interventions to enhance adherence. . IMPLICATIONS FOR NURSING: Nurses should be involved in the planning and implementation of clinical interventions to manage side effects and other barriers to AET adherence.
PURPOSE/ OBJECTIVES: Adjuvant endocrine therapy (AET) has been shown to improve survival in hormone receptor-positive breast cancer survivors, but as many as half do not complete recommended treatment. Management of medication-related side effects and engagement with providers are two potentially modifiable factors, but their associations with adherence are not well understood. The aims were to build on survey results to qualitatively explore survivors' experiences with prescribed AET to (a) describe appraisal and management of AET side effects and (b) deconstruct decisions to initiate, discontinue, or maintain AET. . RESEARCH APPROACH: The authors used a mixed-methods explanatory sequence research design with a qualitative emphasis. . SETTING: Survivors were recruited from a clinical cancer registry maintained at the University of Texas Southwestern Medical Center, which includes the Harold C. Simmons Comprehensive Cancer Center (National Cancer Institute-designated), in Dallas. . PARTICIPANTS: 452 survivors completed a survey, and 30 took part in telephone interviews. . METHODOLOGIC APPROACH: Qualitative methods were used in which the authors recorded and transcribed interviews for analysis and used open coding to reduce data into themes. . FINDINGS: Among adherent survivors, the themes of tolerance of side effects and perseverance were strong. Nonadherent survivors expressed more difficulty managing side effects and perceived fewer benefits when side effects were bothersome. The most common side effects mentioned by all survivors were menopausal symptoms and joint pain; less common side effects were cognitive decline and cardiac distress. Some sought advice from their oncology team. Nonadherent survivors appeared initially motivated to maintain AET but identified a tolerance limit for side effects after which a provider's recommendation was less influential in their decision to maintain or discontinue AET. . INTERPRETATION: This study elucidated adherence as a complex continuum of behaviors, appraisals, and decision points. These insights may be particularly useful in counseling survivors taking AET and promoting timely delivery of clinical interventions to enhance adherence. . IMPLICATIONS FOR NURSING: Nurses should be involved in the planning and implementation of clinical interventions to manage side effects and other barriers to AET adherence.
Entities:
Keywords:
adjuvant endocrine therapy; breast cancer survivors; side effects; survivorship care; symptoms
Authors: Alejandra Hurtado-de-Mendoza; Mark L Cabling; Tania Lobo; Chiranjeev Dash; Vanessa B Sheppard Journal: Clin Breast Cancer Date: 2016-03-31 Impact factor: 3.225
Authors: Duveken B Y Fontein; Caroline Seynaeve; Peyman Hadji; Elysée T M Hille; Willemien van de Water; Hein Putter; Elma Meershoek-Klein Kranenbarg; Annette Hasenburg; Robert J Paridaens; Jean-Michel Vannetzel; Christos Markopoulos; Yasuo Hozumi; John M S Bartlett; Stephen E Jones; Daniel William Rea; Johan W R Nortier; Cornelis J H van de Velde Journal: J Clin Oncol Date: 2013-04-22 Impact factor: 44.544
Authors: Kimberly R Jacob Arriola; Tamara A Mason; Kari Ann Bannon; Carol Holmes; Cecil Lamonte Powell; Kandra Horne; Ruth O'Regan Journal: Patient Educ Couns Date: 2014-01-10
Authors: C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto Journal: Lancet Date: 2011-07-28 Impact factor: 79.321
Authors: Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto Journal: J Clin Oncol Date: 2009-11-30 Impact factor: 44.544
Authors: Bernard Tawfik; Ellen Burgess; Mikaela Kosich; Shoshana Adler Jaffe; Dolores D Guest; Ursa Brown-Glaberman; V Shane Pankratz; Andrew Sussman Journal: Cancer Causes Control Date: 2022-07-13 Impact factor: 2.532
Authors: Shirley M Bluethmann; Catherine M Alfano; Jonathan D Clapp; George Luta; Brent J Small; Arti Hurria; Harvey J Cohen; Steven Sugarman; Hyman B Muss; Claudine Isaacs; Jeanne S Mandelblatt Journal: Breast Cancer Res Treat Date: 2017-06-26 Impact factor: 4.872
Authors: Erin J Aiello Bowles; Cody Ramin; Diana S M Buist; Heather Spencer Feigelson; Sheila Weinmann; Lene H S Veiga; Clara Bodelon; Rochelle E Curtis; Jacqueline B Vo; Amy Berrington de Gonzalez; Gretchen L Gierach Journal: Breast Cancer Res Treat Date: 2022-03-11 Impact factor: 4.872
Authors: K M de Ligt; M Heins; J Verloop; N P M Ezendam; C H Smorenburg; J C Korevaar; S Siesling Journal: Breast Cancer Res Treat Date: 2019-09-11 Impact factor: 4.872
Authors: Kirsti I Toivonen; Devesh Oberoi; Kathryn King-Shier; Katherine-Ann L Piedalue; Joshua A Rash; Linda E Carlson; Tavis S Campbell Journal: Curr Oncol Date: 2021-07-05 Impact factor: 3.677
Authors: Shirley M Bluethmann; Cristina Truica; Heidi D Klepin; Nancy Olsen; Christopher Sciamanna; Vernon M Chinchilli; Kathryn H Schmitz Journal: J Geriatr Oncol Date: 2021-05-26 Impact factor: 3.929
Authors: Maurice J Berkowitz; Carlie K Thompson; Laura T Zibecchi; Minna K Lee; Elani Streja; Jacob S Berkowitz; Cachet M Wenziger; Jennifer L Baker; Maggie L DiNome; Deanna J Attai Journal: J Cancer Surviv Date: 2020-08-17 Impact factor: 4.062